Neurologix needs partner or funds to move Parkinson's gene therapy towards Phase III
This article was originally published in Scrip
Neurologix is planning to submit a Phase III trial design under a special protocol assessment (SPA) to the US FDA later this year for NLX-P101, its glutamic acid decarboxylase gene therapy for Parkinson's disease, having discussed the product's recently-obtained Phase II data with the agency. However, given that its current finances will take it only through until the end of this year, the company's success or otherwise in raising support for the trial will test just how committed investors or large companies are to gene therapeutics.
You may also be interested in...
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.